⁃ Patients ages 18 to 70 years old at the time of enrollment.

⁃ Patients weighing at least 42 kg

⁃ Patient with the hematologic malignancies described below, as well as an HLA matched related donor, HLA matched unrelated donor, a haploidentical related donor, or a one antigen mismatched unrelated donor. HLA matching includes HLA A, B, C, and DR-B1.

⁃ Patients must have one of the following diseases:

⁃ Acute myeloid leukemia (AML):

⁃ a. With one or more high-risk features defined as: (i) Greater than 1 cycle of induction therapy required to achieve remission; (ii) Preceding myelodysplastic syndrome (MDS);

⁃ Presence of FLT3 mutations or internal tandem duplication or other mutations designated as adverse-risk by the ELN Leukemia Net AML Classification (see Appendix 2):

⁃ Adverse:

⁃ t(6;9)(p23;q34.1); DEK-NUP214

⁃ t(v;11q23.3); KMT2A rearranged

⁃ t(9;22)(q34.1;q11.2); BCR-ABL1

⁃ inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2,MECOM(EVI1)

• 5 or del(5q); -7; -17/abn(17p)

⁃ Complex karyotype, monosomal karyotype

⁃ Wild-type NPM1 and FLT3-ITDhigh

⁃ Mutated RUNX1

⁃ Mutated ASXL1

⁃ Mutated TP53 (iv) FAB M6 or M7 classification; (v) Adverse cytogenetics: -5, del 5q, -7, del7q, abnormalities involving 3q, 9q, 11q, 20q, 21q, 17, +8 or complex karyotype [> 3 abnormalities]; or other mutations designated as adverse-risk by the ELN criteria; (vi) Treatment-related AML (vii) Primary induction failure with partial response to therapy who achieve adequate cytoreduction (viii) Aplastic/hypoplastic marrow with or without detectable persistent disease after induction chemotherapy or after salvage chemotherapy.

⁃ (ix) Have minimal residual disease by flow cytometry, FISH, detection of disease related mutations or cytogenetic abnormality after first course of induction chemotherapy (x) Have relapsed after prior allogeneic hematopoietic transplant

⁃ AND

⁃ b. Patients must be in one of the following (i) CR: complete remission, (ii) CRi: CR with incomplete hematologic recovery, or (iii) MLFS: morphological leukemia-free state with less than 5% bone marrow blasts.

⁃ (iv) If not in either of the above i-iii, then may be in either of the following:

⁃ Primary induction failure with partial response to therapy who achieve adequate cytoreduction

⁃ Aplastic/hypoplastic marrow with or without detectable persistent disease after induction chemotherapy or after salvage chemotherapy

⁃ Myelodysplastic syndromes (MDS):

⁃ a. De novo MDS with intermediate or high-risk IPSS scores, chronic myelomonocytic leukemia (CMML) or treatment-related MDS. Patients with intermediate-1 features should have failed to respond to hypomethylating agent therapy. .

⁃ Patients must have less than 10% bone marrow blasts

⁃ Chronic myeloid leukemia (CML):

⁃ Failed to achieve cytogenetic remission or have cytogenetic relapse after treatment with at least 2 tyrosine kinase inhibitors, or

⁃ Accelerated phase or blast phase at any time, or

⁃ Intolerant of available TKIs

⁃ Performance score of at least 70% by Karnofsky or 0 to 1 by ECOG.

⁃ Adequate major non-hematopoietic organ system function as demonstrated by:

⁃ Serum creatinine clearance equal or more than 50 ml/min (calculated with Cockcroft-Gault formula).

⁃ Bilirubin equal or less than 1.5 mg/dL except for Gilbert's disease. ALT or AST equal or less than 200 U/L for adults. Conjugated (direct) bilirubin less than 2x upper limit of normal.

⁃ Left ventricular ejection fraction equal or greater than 45%.

⁃ Diffusing capacity for carbon monoxide (DLCO) equal or greater than 60% predicted corrected for hemoglobin.

⁃ Ability to understand and willingness to sign the written informed consent document.

⁃ Sexually active males and females of childbearing potential must agree to use a form of contraception considered effective and medically acceptable by the Investigator while on study.